ATLnsider
@ATLnsider
Followers
3K
Following
13K
Media
367
Statuses
4K
Investor with over 25 years experience specializing in the biotech & pharmaceutical industries. My tweets are my own opinions. Please do your own research.
Atlanta
Joined May 2011
Who else is Anson Funds Moez Kassam giving up? @stockmannnbroo says trading bots are another weapon used by Anson Funds’ “But the real nuclear bomb here is this: They work with various groups in China that have access to thousands of trading bots. These bots are all linked
Anson Funds spilling the beans on illegal activities taking place at CIBC, TD Bank and Jefferies. Will it be enough to keep their criminal CEO, Moez Kassam out of jail? https://t.co/VvuzNBfI8Z
#anson #funds
@BreakingNews
@RJRCapital
@SEC_Enforcement
@zerohedge
@WhiteHouse
#moez
9
36
112
What ATL-DC ( Autologous tumor lysate-pulsed dendritic cell) vaccine UCLA uses in its clinical trials? According to UCLA Drs. Linda Liau & Leia Nghiemphu it’s $NWBO #DCVax-L. Listen to 37:20 minute mark of video UCLA Brain Tumor Conference Updates in Experimental Therapies:
3
12
81
$NWBO takes out a new loan with Streeter for $5 million +. apparently, readying for #DCVax imminent commercialization. I don’t see any warrants, options or stock conversion language. Looks like a straight loan:
3
7
130
$NWBO This article is just wonderful! It is really amazing that Dr. Czerniecki has treated more than 300 people with dendritic cell therapy. https://t.co/T1a4aN5jHY
https://t.co/Xu2rps9FDa At her sister’s urging, Carroll reached out to Moffitt Cancer Center in Tampa for a
penniesinaction.org
4
6
52
$NWBO More on Northwest Biotherapeutics strategic move to transition from R&D biotech to near-commercial cell therapy manufacturer. Northwest Bio bought Advent BioServices for $1.9 million cash plus paying off old debt. No new shares were issued; 19 million company securities
$NWBO “We are excited to have completed the necessary conditions for closing the acquisition of Advent, and to be moving into position for potential significant scale-up," commented Linda Powers, the Company's CEO. “We believe this integration can also help accelerate
2
31
166
$NWBO folk, quick reminder: 2024 10-K "The Company has also been in negotiations since early Q4 2024 for potential acquisition of another company with a dendritic cell related technology." This company is clearly not Advent Bioservices. So what else are we gonna add to the mix?
6
10
80
Very nice article about $NWBO acquisition of Advent Bioservices & the future implications for #DCVax dendritic cell cancer vaccine platform technology globally & to potentially treat all solid tumor cancers:
How Northwest Biotherapeutics’ acquisition of Advent BioServices may reshape its cell therapy strategy https://t.co/nSAQLQ6Wkj
#NorthwestBiotherapeutics #AdventBioServices #DCVax #Immunotherapy #CellTherapy #BiotechNews #GBM #NWBO #CancerVaccine #BiotechAcquisition
0
11
106
One of many $NWBO #DCVax dominoes that will be falling in succession soon‼️
📣Advent has been acquired by $NWBO!📣 https://t.co/1J8bLiK8C9
2
8
93
I spoke to $NWBO this morning & they said this is not a new shelf-offering. It’s a renewal of the existing S-3, that has to be renewed every 3 years, because the existing S-3 is expiring. There are no additional shares being offered. #DCVax MHRA approval remains the main focus.
2
22
160
This is what I believe $NWBO will do with #HealthBank that Linda recently updated its USPTO trademark in the U.S. to supplement #DCVax revenue & create a separate wholly-owned profit center & revenue stream, like Advent Bioservices & Flaskworks: https://t.co/kdiOYf861I
1
7
80
➡️NWBO's non-testifying expert identified⬅️ $NWBO's non-testifying expert: Joshua Mitts The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) On October 13th we saw Defendant Market Makers request the Court enter an order to identify "all
6
21
126
I asked AI the following questions about $NWBO #DCVax, Flaskworks EDEN & the UK new SI 87 regulation: “Please review the provisions of the U.K. SI number 87: the human medicines (amendment) (modular manufacture and point of care) regulations 2025, then analyze how Northwest
investorshub.advfn.com
ATLnsider: I asked AI the following questions about NWBio, DCVax, Flaskworks EDEN and the U.K. new SI 87 regulation: Please review the provisions of the U.K...
0
4
42
$NWBO "...This (October 16th) article speaks to the fact that DCVax could potentially be tumor / tissue agnostic & may treat all or most malignant solid tumor cancers" A number of big market makers allegedly tried to destroy this company, which has a promising treatment/cure
This paper was published today 10/16/2025. It has some profound statements about $NWBO #DCVax-L dendritic cell vaccine technology platform including: “DC vaccines loaded with tumor lysates are a promising treatment strategy with potential therapeutic efficacy demonstrated in
3
42
166
This paper was published today 10/16/2025. It has some profound statements about $NWBO #DCVax-L dendritic cell vaccine technology platform including: “DC vaccines loaded with tumor lysates are a promising treatment strategy with potential therapeutic efficacy demonstrated in
3
25
132
NICE rejecting vorasidenib = fantastic news. MHRA approved it, but NICE just said no because it costs ~$500K/year on PFS, no OS. Lifetime cost per patient $1-2M. With economies of scale, thanks to Flaskworks, $NWBO will cost a fraction. Ask yourself: Why would the NHS fund
2
4
41
I signed PPA petition. Hopefully this Bill will pass & will help $NWBO #DCVax-Direct patients & help DCVax-L patients to get combination treatments sooner, such as poly-ICLC & other immune-boosting agents. DCVax-L as a monotherapy to treat nGBM & rGBM should be approved by FDA
virtualtrials.org
Empowering brain tumor patients with support, education, advocacy, and research funding.
1
5
61
$NWBO I just supported the Promising Pathway Act (PPA) 2.0 petition! Join me in advancing this cause:
virtualtrials.org
Empowering brain tumor patients with support, education, advocacy, and research funding.
7
17
95